MNC pharma companies to control 8% of $20bn worth Indian medicines market by 2015. According to a FICCI study more than 60% of trials in India is conducted by Global Big Pharma companies. Indian Clinical Research arena is often compared to the Indian outsourcing success and hte wave of BPO industry success in India.
Multi national companies that launched their own captive BPO centres India have now sold them to Indian vendors, that trend has grown, the likes of , GE, Citi Bank, all have sold their captive centres to Indian vendors
In curent wave or Indian CRO success in clinical research is compared to such trends. There may be a possiblity that the likes of Novartis, Pfizer, Lilly, Sanofi, GSK can sell their captive centres that focus on clinical research to Indian CRO’s.
But for the time being such ambitions by Indian CRO will remain as pipe dream untill they will move away from “I can do it cheaper and faster than in west”- sales pitch. And gains credibility and resources to offer value added service to Global Pharma
For example Indian CRO can offer backend integration with Indian Medicinal chemistry experts and companies to provide drug re-licencing /re-positioning services. They need to think about offering these value add services. Following are some of the areas Indian CRO’s can look
1. what happens to failed Clinical Trial and how can Indian CRO help Global Pharma to Drug repositioning/Re-profiling of drugs
2. How can Indian CRO provide Pharmacogenomics services with clinical trial
3. How can Indian CRO help in personalized medicine initiatives
4. Even though it serves the vested interests of Global Pharma how can Indian CRO help in Extending patents of existing drugs with ANDA and NDDS
5. Pharmacovigilance and Post -Market Surveillance for Risk Assesement and Risk Mitigation
6. Data Warehousing and Data Mining by integrating clinical and non clinical data from multiple studies
7. Drug Life cycle management services
8. Generating Key opinion leaders and KOL platform by using data from multiple trials and resources
9. Premarketing Clinical Drug Safety and Risk Assessment
10. Designing Pharmacoepidemiology and Pharmacoecconomics stratgey and Aiding Evidence based pharmacotherapy
Filed under: microarray | Tagged: Clinical Trial, CRO, Drug Safety, Evidence based pharmacotherapy, health sciences global business unit, HSGBU, Indian CRO, oracle, Oracle health sciences global business unit, Pharmacoecconomics, Pharmacoepidemiology, Pharmacogenomics, pharmacovigilance | Leave a comment »